# Imatinib in Systemic Sclerosis

> **NCT00506831** · PHASE1,PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 9 (actual)

## Conditions studied

- Scleroderma, Systemic

## Interventions

- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT00506831
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00506831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00506831, "Imatinib in Systemic Sclerosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00506831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*